BioAdaptives (BDPT) Director Mark Frissora Receives Preferred Stock Award

What Happened

• Mark P. Frissora, a director of BioAdaptives, was issued 15,152 shares of Series D Convertible Preferred Stock on August 1, 2026. The filing reports the shares were acquired at $0.00 (i.e., issued as compensation) and recorded as a derivative transaction on the Form 4. This was an award for board services rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-08-01; Filing date: 2026-08-04.
• Transaction type/code: Other acquisition or disposition (code J); price reported $0.00.
• Instrument: Series D Convertible Preferred Stock (derivative), 15,152 shares.
• Shares owned after transaction: Not specified in the filing.
• Footnote highlights:
  • F1: These preferred shares were issued as compensation under the Board of Directors Agreement dated Feb 3, 2025.
  • F2: Each Series D preferred share is convertible into 100 shares of common stock, subject to a 4.9% beneficial ownership limitation; conversion is not permitted until six months after issuance (except upon liquidation). Each preferred share carries 100 votes at stockholder meetings. The conversion right does not expire.
• No indication in the filing that this was a late submission.

Context

• This was a compensation award (no cash exchanged) rather than a market purchase; such grants compensate service and do not by themselves indicate insider trading sentiment. Because these are convertible preferred shares with a conversion limit and a six-month conversion delay, they are not immediately equivalent to common shares and come with specific voting and ownership constraints.